Keyword: Olivier Brandicourt
Sanofi, aiming to sharpen its focus by offloading its EU generics, is reportedly drawing shoppers from across the globe. The deal could be worth $2B.
More than 70 mothers in the Philippines whose children were vaccinated against dengue filed a criminal complaint against government and company officials.
Now that Republicans in Congress have passed tax reform, the pharma sector could be due for a long-anticipated M&A rebound.
Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.
Sanofi’s loss is Almirall’s gain. In its second diabetes exec shift since last May, EVP Peter Guenter jumped to the top job at derm-focused Almirall.
FiercePharma kept track as the industry launched drugs, made deals, lost patents, shrank, grew, innovated and revolutionized since 2007. Here's how.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Sanofi Chairman Serge Weinberg says the French drug giant doesn’t need any new purchases.
Sanofi may be late to the pricing-pledge party, but it’s not stopping with 9.9% price-hike limits. Instead, it's promising to keep any price increases at or below a health inflation index projected at 5.4% in 2017.